Jaar: 2023

Handmatige gegevensprocessen verhinderen groei bij 87% scale-upbedrijven, aldus nieuw onderzoek van Jitterbit

78% van de leiders van scale-upbedrijven die in Europa werden geënquêteerd, plannen om hun bedrijfsactiviteiten de komende 12 maanden met meer dan 40% te laten...

UL Solutions Publicly Files Registration Statement for Proposed Initial Public Offering

NORTHBROOK, Ill.–(BUSINESS WIRE)– UL Solutions Inc. (“UL Solutions”) today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities...

Sofinnova Partners Enhances Leadership in Medtech Acceleration with Key Appointments

Experienced entrepreneurs, Mano Iyer and Cécile Dupont, appointed as Partners in the Sofinnova MD Start team, signaling a strategic expansion of the partnership PARIS–(BUSINESS WIRE)–...

FourKites Launches Inbound Visibility Solution to Enhance End-to-End, Shipment- and Order-Level Insights Across Suppliers

New multimodal solution fills visibility gaps, improves workforce productivity, enhances inventory management and accelerates time-to-value for FourKites customers AMSTERDAM–(BUSINESS WIRE)– Leading supply chain visibility provider...

De 25e China Hi-Tech beurs begint op 15 november in Shenzhen

SHENZHEN, China–(BUSINESS WIRE)– De 25e China Hi-Tech Fair (CHTF) gaat van start op 15-19 november 2023 in Shenzhen, China. De CHTF van dit jaar is...

Manual data processes hindering growth for 87% of scale-ups, new Jitterbit research reveals

78% of leaders of scale-ups surveyed across Europe plan to grow their business by over 40% in the next 12 months but research shows they...

Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1

Acquisition extends global capabilities in AAV and plasmid gene therapy manufacturing for Ajinomoto, Co. Inc., diversifying and strengthening their current contract development and manufacturing services...

The 25th China Hi-Tech Fair to Kick Off on November 15 in Shenzhen

SHENZHEN, China–(BUSINESS WIRE)– The 25th China Hi-Tech Fair (CHTF) will commence on November 15-19, 2023 in Shenzhen, China. This year’s CHTF is set to be...

SES’s Fifth and Sixth O3b mPOWER Satellites Successfully Launched

With six satellites, SES’s second-generation medium earth orbit system will be ready to provide high-performance connectivity services around the globe from early Q2 2024. CAPE...

Shandong in China start promotieactiviteit van “Vriendelijk Shandong, bijzonder Shandong”

BEIJING–(BUSINESS WIRE)– Een speciale promotieactiviteit getiteld “Vriendelijk Shandong, bijzonder Shandong” ging op 10 november van start in het Beijing Exhibition Center van China, waarbij de...

Alnylam presenteert positieve resultaten van de KARDIA-1 Fase 2 studie met dosisveranderingen van Zilebesiran, een RNAi-therapeuticum in ontwikkeling voor de behandeling van hypertensie bij patiënten met een hoog cardiovasculair risico

– Zilebesiran voldoet aan het primaire eindpunt met een placebogecorrigeerde verlaging tot 16,7 mmHg van de 24-uurs gemiddelde systolische bloeddruk na drie maanden behandeling –...

AGCO zet technologietransformatie verder om sectorleider te worden op gebied van intelligente oplossingen voor de landbouw

Toevoeging van tech-stack van FarmFacts Digital Assets en AGCO-ventures behoren tot de volgende stappen DULUTH, Ga.–(BUSINESS WIRE)– Na de onlangs aangekondigde Joint Venture (JV) met...

Guidewire Innsbruck Release Empowers Insurers to Transform Customer Experiences with Jutro Digital Platform

NASHVILLE, Tenn.–(BUSINESS WIRE)– CONNECTIONS CONFERENCE – Guidewire (NYSE: GWRE) announces Innsbruck, its latest cloud release, which helps insurers take advantage of market opportunities with advancements...

AGCO Continues Technology Transformation to Become an Industry Leader in Smart Farming Solutions

Tech Stack Addition of FarmFacts Digital Assets and AGCO Ventures Among Next Steps DULUTH, Ga.–(BUSINESS WIRE)– Following the recently announced transformational Joint Venture (JV) with...

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

– Zilebesiran Met Primary Endpoint Demonstrating Up to 16.7 mmHg Placebo-Adjusted Reduction of 24-Hour Mean Systolic Blood Pressure at Three Months of Treatment – –...